Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Machine learning to understand risks for severe COVID-19 outcomes: a retrospective cohort study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US health-care system.
Wei Q, Mease PJ, Chiorean M, Iles-Shih L, Matos WF, Baumgartner A, Molani S, Hwang YM, Belhu B, Ralevski A, Hadlock J. Wei Q, et al. Among authors: chiorean m. Lancet Digit Health. 2024 May;6(5):e309-e322. doi: 10.1016/S2589-7500(24)00021-9. Lancet Digit Health. 2024. PMID: 38670740 Free PMC article.
Risk factors for severe COVID-19 outcomes: a study of immune-mediated inflammatory diseases, immunomodulatory medications, and comorbidities in a large US healthcare system.
Wei Q, Mease PJ, Chiorean M, Iles-Shih L, Matos WF, Baumgartner A, Molani S, Hwang YM, Belhu B, Ralevski A, Hadlock J. Wei Q, et al. Among authors: chiorean m. medRxiv [Preprint]. 2023 Jun 28:2023.06.26.23291904. doi: 10.1101/2023.06.26.23291904. medRxiv. 2023. PMID: 37425752 Free PMC article. Updated. Preprint.
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies.
Sandborn WJ, Vermeire S, Peyrin-Biroulet L, Dubinsky MC, Panes J, Yarur A, Ritter T, Baert F, Schreiber S, Sloan S, Cataldi F, Shan K, Rabbat CJ, Chiorean M, Wolf DC, Sands BE, D'Haens G, Danese S, Goetsch M, Feagan BG. Sandborn WJ, et al. Among authors: chiorean m. Lancet. 2023 Apr 8;401(10383):1159-1171. doi: 10.1016/S0140-6736(23)00061-2. Epub 2023 Mar 2. Lancet. 2023. PMID: 36871574 Free article. Clinical Trial.
Early recapture of response with tofacitinib 10 mg twice daily in patients with ulcerative colitis in OCTAVE Open following dose reduction or treatment interruption in OCTAVE Sustain.
Allegretti JR, Gecse KB, Chiorean MV, Argollo M, Guo X, Lawendy N, Su C, Mundayat R, Paulissen J, Salese L, Irving PM. Allegretti JR, et al. Among authors: chiorean mv. J Gastroenterol Hepatol. 2024 Feb;39(2):264-271. doi: 10.1111/jgh.16386. Epub 2023 Nov 12. J Gastroenterol Hepatol. 2024. PMID: 37953548
Surgery for Crohn's Disease Is Associated with a Dysbiotic Microbiome and Metabolome: Results from Two Prospective Cohorts.
Lewis JD, Daniel SG, Li H, Hao F, Patterson AD, Hecht A, Brensinger CM, Wu GD, Bittinger K; DINE-CD and SPARC IBD Investigators; Kaur M, Dassopoulos T, Snapper SB, Korzenik JR, Bohm M, Raffals L, Beniwal-Patel P, Hudesman D, Russ K, Brook L, Pekow J, Cross R, Wong U, Bishu S, Bewtra M, Lewis JD, Duerr R, Saha S, Caldera F, Scoville E, Deepak P, Ciorba M. Lewis JD, et al. Cell Mol Gastroenterol Hepatol. 2024 May 13:S2352-345X(24)00111-5. doi: 10.1016/j.jcmgh.2024.05.005. Online ahead of print. Cell Mol Gastroenterol Hepatol. 2024. PMID: 38750900 Free article.
Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
Yarur AJ, Chiorean MV, Panés J, Jairath V, Zhang J, Rabbat CJ, Sandborn WJ, Vermeire S, Peyrin-Biroulet L. Yarur AJ, et al. Among authors: chiorean mv. J Crohns Colitis. 2024 Jan 20:jjae007. doi: 10.1093/ecco-jcc/jjae007. Online ahead of print. J Crohns Colitis. 2024. PMID: 38245818
85 results